Dual role of metformin as a chemosensitizer and normal tissue protectant: Does it improve the therapeutic ratio? – A narrative review
Annals of Oncology Research and Therapy · 2027
DOI: 10.4103/aort.aort_10_26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Oncology Research and Therapy, 2027. Verfasst von Tanisha Gupta und 3 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Metformin, a widely used first-line oral hypoglycemic agent for type 2 diabetes mellitus, has gained increasing attention for its potential anticancer properties. Emerging evidence suggests that diabetes and its metabolic environment may influence cancer incidence, progression, and mortality, while glucose-lowering therapies such as metformin may modify these risks. Preclinical and clinical studies indicate that metformin may enhance the efficacy of chemotherapy through mechanisms such as AMP-activated protein kinase activation, inhibition of the mammalian target of the rapamycin pathway, reduction of insulin-mediated proliferative signaling, metabolic reprogramming of tumor cells, and modulation of the tumor microenvironment. Evidence also suggests preferential tumor targeting with limited toxicity to normal tissues, supporting its potential to improve the therapeutic ratio. However, much of the available data remain preclinical or retrospective. Overall, metformin appears to be a promising, safe, and cost-effective adjunct in cancer management, but well-designed prospective clinical trials are necessary to confirm its definitive role in routine oncologic practice. This narrative review involved literature search of electronic databases, including PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials, to explore the role of metformin as a chemosensitizing agent and normal tissue protectant in cancer therapy.
Zitieren
APA
Gupta, T., Khan, M., Akram, M., & Hussain, M. A. B. (2027). Dual role of metformin as a chemosensitizer and normal tissue protectant: Does it improve the therapeutic ratio? – A narrative review. Annals of Oncology Research and Therapy. https://doi.org/10.4103/aort.aort_10_26
Vancouver
Gupta T, Khan M, Akram M, Hussain MAB. Dual role of metformin as a chemosensitizer and normal tissue protectant: Does it improve the therapeutic ratio? – A narrative review. Annals of Oncology Research and Therapy. 2027. doi:10.4103/aort.aort_10_26
BibTeX
@article{Gupta2027,
author = {Gupta, Tanisha and Khan, Mohsin and Akram, Mohammad and Hussain, M. A. Bilal},
title = {Dual role of metformin as a chemosensitizer and normal tissue protectant: Does it improve the therapeutic ratio? – A narrative review},
journal = {Annals of Oncology Research and Therapy},
year = {2027},
doi = {10.4103/aort.aort_10_26}
}
EUVIMED